Group One Trading
CLDX icon

Group One Trading’s Celldex Therapeutics CLDX Stock Holding History

Group One Trading’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.44K Sell
200
-1,300
-87% -$42K ﹤0.01% 6564
2026
Q1 		$47.6K Buy
+1,500
New +$40.9K ﹤0.01% 5295
2025
Q4 		– Sell
-13,000
Closed -$336K – 8229
2025
Q3 		$336K Buy
13,000
+7,600
+141% +$176K ﹤0.01% 4120
2025
Q2 		$110K Sell
5,400
-300
-5% -$5.84K ﹤0.01% 4886
2025
Q1 		$103K Buy
5,700
+4,900
+613% +$109K ﹤0.01% 4577
2024
Q4 		$20.2K Sell
800
-10,800
-93% -$293K ﹤0.01% 5680
2024
Q3 		$394K Buy
11,600
+3,500
+43% +$133K ﹤0.01% 3038
2024
Q2 		$300K Sell
8,100
-4,200
-34% -$158K ﹤0.01% 3049
2024
Q1 		$516K Sell
12,300
-27,400
-69% -$1.13M ﹤0.01% 2697
2023
Q4 		$1.57M Buy
39,700
+30,200
+318% +$888K ﹤0.01% 2072
2023
Q3 		$261K Sell
9,500
-3,200
-25% -$100K ﹤0.01% 3572
2023
Q2 		$431K Buy
12,700
+2,500
+25% +$84.3K ﹤0.01% 3174
2023
Q1 		$367K Sell
10,200
-69,900
-87% -$3.02M ﹤0.01% 3053
2022
Q4 		$3.57M Buy
80,100
+2,200
+3% +$78.5K 0.01% 1372
2022
Q3 		$2.19M Sell
77,900
-16,000
-17% -$491K ﹤0.01% 1835
2022
Q2 		$2.53M Buy
93,900
+22,400
+31% +$651K ﹤0.01% 1839
2022
Q1 		$2.44M Sell
71,500
-16,400
-19% -$524K ﹤0.01% 2214
2021
Q4 		$3.4M Buy
87,900
+2,300
+3% +$100K ﹤0.01% 2063
2021
Q3 		$4.62M Buy
85,600
+13,600
+19% +$638K 0.01% 1777
2021
Q2 		$2.41M Sell
72,000
-52,800
-42% -$1.45M ﹤0.01% 2441
2021
Q1 		$2.57M Buy
124,800
+52,400
+72% +$1.2M ﹤0.01% 2183
2020
Q4 		$1.27M Buy
72,400
+57,300
+379% +$1.03M ﹤0.01% 2436
2020
Q3 		$224K Sell
15,100
-6,500
-30% -$76.1K ﹤0.01% 3562
2020
Q2 		$281K Buy
+21,600
New +$95.7K ﹤0.01% 3104
2019
Q4 		– Sell
-24,000
Closed -$51K – 5160
2019
Q3 		$51K Buy
24,000
+20,000
+500% +$46.3K ﹤0.01% 3956
2019
Q2 		$11K Buy
+4,000
New +$13.6K ﹤0.01% 4382
2018
Q3 		– Sell
-2,247
Closed -$17K – 5224
2018
Q2 		$17K Buy
2,247
+67
+3% +$896 ﹤0.01% 4430
2018
Q1 		$76K Sell
2,180
-6,013
-73% -$233K ﹤0.01% 3417
2017
Q4 		$349K Buy
8,193
+6,833
+502% +$293K ﹤0.01% 2538
2017
Q3 		$58K Sell
1,360
-3,620
-73% -$136K ﹤0.01% 3550
2017
Q2 		$185K Buy
4,980
+1,353
+37% +$59.8K ﹤0.01% 2697
2017
Q1 		$196K Sell
3,627
-3,406
-48% -$177K ﹤0.01% 2535
2016
Q4 		$373K Sell
7,033
-2,754
-28% -$157K ﹤0.01% 1976
2016
Q3 		$593K Sell
9,787
-653
-6% -$40.7K 0.01% 1690
2016
Q2 		$687K Buy
10,440
+1,033
+11% +$65.6K 0.01% 1503
2016
Q1 		$533K Sell
9,407
-22,793
-71% -$2.56M 0.01% 1632
2015
Q4 		$7.57M Sell
32,200
-14,587
-31% -$3.18M 0.09% 230
2015
Q3 		$7.4M Sell
46,787
-13,333
-22% -$3.77M 0.1% 222
2015
Q2 		$22.7M Buy
60,120
+8,227
+16% +$3.27M 0.32% 44
2015
Q1 		$21.7M Buy
51,893
+24,260
+88% +$8.68M 0.34% 36
2014
Q4 		$7.57M Buy
27,633
+9,046
+49% +$2.25M 0.11% 174
2014
Q3 		$3.61M Sell
18,587
-7,206
-28% -$1.57M 0.06% 407
2014
Q2 		$6.31M Buy
25,793
+3,226
+14% +$728K 0.1% 223
2014
Q1 		$5.98M Buy
22,567
+7,020
+45% +$2.69M 0.1% 176
2013
Q4 		$5.65M Buy
15,547
+1,594
+11% +$614K 0.09% 227
2013
Q3 		$7.42M Buy
13,953
+7,766
+126% +$2.66M 0.14% 122
2013
Q2 		$1.45M Buy
+6,187
New +$1.22M 0.04% 595

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Group One Trading's CLDX Position: Q1 2026 in Review

Group One Trading sold out of Celldex Therapeutics (CLDX) in Q1 2026, closing a stake of 748 shares — an estimated $20.4K sold.

Group One Trading first reported a position in CLDX in Q2 2013 and held it in 44 quarters. The position peaked at $9.27M in Q1 2015. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Group One Trading reported no remaining Celldex Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 748 Celldex Therapeutics shares in Q1 2026, an estimated $20.4K.
  • Group One Trading first reported a position in Celldex Therapeutics in Q2 2013 and held it in 44 quarters.
  • Group One Trading's Celldex Therapeutics position peaked at $9.27M in Q1 2015.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.